Evolving Treatment Paradigms

FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Share / Send / Save

Clinical practice recommendations for HAE management

In 2012, guidelines from two international associations — the Hereditary Angioedema International Working Group (HAWK) and the World Allergy Organization (WAO) — were published outlining their recommendations for the treatment of HAE attacks.1,2

Both guidelines were developed by international HAE experts, and only physicians who were responsible for treatment prescription were allowed to vote on the recommendations.1,2

In 2013, guidelines from the US Hereditary Angioedema Association Medical Advisory Board were also published outlining their recommendations for the treatment of HAE.3

Several on-demand treatment options are available and are described in the literature. Multiple therapies have been recommended, and no one product has been endorsed. FIRAZYR is one option for the treatment of acute HAE attacks.

HAWK: evidence-based treatment guidelines that support a proactive, patient-centric approach to HAE treatment1

Select recommendations in the guidelines include:

  • All attacks, regardless of location, are eligible for treatment as soon as they are clearly recognized by the patient. (recommendation 11)
  • On-demand treatment for acute attacks should be the initial goal of therapy for all patients. (recommendation 13)
  • Whenever possible and allowed by drug-specific summary product characteristics, patients should have an on-demand treatment medicine to treat acute attacks at home and should be trained to self-administer these medicines (recommendation 10)

WAO: consensus-based recommendations for the diagnosis and treatment of HAE2

Select recommendations in the guidelines include:

  • All attacks causing debilitation/dysfunction and/or involving the face, neck or abdomen should be considered for on-demand treatment. Treatment of attacks affecting the upper airways is mandatory. (recommendation 2)
  • All patients with HAE should have an action plan and product available to treat an attack of HAE. (recommendation 15)
  • All patients should have on-demand treatment for 2 attacks and carry their on-demand treatment with them at all times. (recommendations 8 and 9)
  • All patients who are provided with on-demand treatment licensed for self-administration should be taught to self-administer. (recommendation 16)

HAEA: recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency3

Select recommendations in the guidelines include:

  • All attacks, regardless of location, should be considered for treatment as soon as they are clearly recognized
  • To be most effective, on-demand treatment of attacks should be administered early in the attack